1,734 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B Buy
Article Searches
AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales http://www.zacks.com/stock/news/354603/astrazenecas-azn-q4-earnings-beat-new-drugs-drive-sales?cid=CS-ZC-FT-354603 Feb 14, 2019 - AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
Top Research Reports for ExxonMobil, Merck & Danaher http://www.zacks.com/research-daily/213347/top-research-reports-for-exxonmobil-merck-danaher?cid=CS-ZC-FT-213347 Feb 13, 2019 - Top Research Reports for ExxonMobil, Merck & Danaher
MacroGenics’ Public Offering to Raise Funds for R&D, Marketing Is a Smart Move http://www.gurufocus.com/news/814733/macrogenics-public-offering-to-raise-funds-for-rd-marketing-is-a-smart-move Feb 13, 2019 - MacroGenics’ Public Offering to Raise Funds for R&D, Marketing Is a Smart Move, Stocks: MGNX,OTCQX:RHHBY,MRK, release date:Feb 13, 2019
Bristol-Myers' Sprycel Gets European Nod for Label Expansion http://www.zacks.com/stock/news/354050/bristol-myers-sprycel-gets-european-nod-for-label-expansion?cid=CS-ZC-FT-354050 Feb 12, 2019 - Bristol-Myers' (BMY) oncology drug, Sprycel in combination with chemotherapy gets EC approval to treat pediatric patients with newly diagnosed Ph+ ALL.
Seattle Genetics' Adcetris Gets EC Nod for Label Expansion http://www.zacks.com/stock/news/354019/seattle-genetics-adcetris-gets-ec-nod-for-label-expansion?cid=CS-ZC-FT-354019 Feb 12, 2019 - Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.
Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review http://www.zacks.com/stock/news/353912/pfizer-sbla-for-kidney-cancer-drug-combo-gets-priority-review?cid=CS-ZC-FT-353912 Feb 12, 2019 - Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets priority review in the United States. The decision is expected in June.
Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer http://www.zacks.com/stock/news/353843/mercks-keytruda-gets-fda-priority-review-for-head-neck-cancer?cid=CS-ZC-FT-353843 Feb 12, 2019 - Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Stock Market News For Feb 12, 2019 http://www.zacks.com/stock/news/353887/stock-market-news-for-feb-12-2019?cid=CS-ZC--353887 Feb 12, 2019 - Markets closed mostly higher on Monday as fresh rounds of trade talks between the United States and China began.
Tracking Dan Loeb's Third Point Portfolio - Q4 2018 Update https://seekingalpha.com/article/4240076-tracking-dan-loebs-third-point-portfolio-q4-2018-update?source=feed Feb 12, 2019 - Dan Loeb's 13F portfolio value decreased from $12.84B to $6.5B this quarter. The number of positions decreased from 31 to 22.Third Point increased Campbell Soup and Saleforce.com, while dropping Unite
Week 7 Breakout Forecast: Short-Term Picks To Give You An Edge https://seekingalpha.com/article/4239860-week-7-breakout-forecast-short-term-picks-give-edge?source=feed_all_articles Feb 11, 2019 - Two new Breakout Stocks for Week 7 with better than 10% short-term upside potential.Two Best of the Dow 30 for Week 5 mega-cap selections based on breakout model characteristics are: Merck & Co. and t

Pages: 12345678...174

<<<Page 3>